251 related articles for article (PubMed ID: 11991997)
1. Hepatic DR5 induces apoptosis and limits adenovirus gene therapy product expression in the liver.
Zhang HG; Xie J; Xu L; Yang P; Xu X; Sun S; Wang Y; Curiel DT; Hsu HC; Mountz JD
J Virol; 2002 Jun; 76(11):5692-700. PubMed ID: 11991997
[TBL] [Abstract][Full Text] [Related]
2. Enhanced proliferation and increased IFN-gamma production in T cells by signal transduced through TNF-related apoptosis-inducing ligand.
Chou AH; Tsai HF; Lin LL; Hsieh SL; Hsu PI; Hsu PN
J Immunol; 2001 Aug; 167(3):1347-52. PubMed ID: 11466352
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines.
Shetty S; Gladden JB; Henson ES; Hu X; Villanueva J; Haney N; Gibson SB
Apoptosis; 2002 Oct; 7(5):413-20. PubMed ID: 12207174
[TBL] [Abstract][Full Text] [Related]
4. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity.
Mirandola P; Ponti C; Gobbi G; Sponzilli I; Vaccarezza M; Cocco L; Zauli G; Secchiero P; Manzoli FA; Vitale M
Blood; 2004 Oct; 104(8):2418-24. PubMed ID: 15205263
[TBL] [Abstract][Full Text] [Related]
5. IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway.
Shin EC; Ahn JM; Kim CH; Choi Y; Ahn YS; Kim H; Kim SJ; Park JH
Int J Cancer; 2001 Jul; 93(2):262-8. PubMed ID: 11410875
[TBL] [Abstract][Full Text] [Related]
6. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5.
Kim H; Kim EH; Eom YW; Kim WH; Kwon TK; Lee SJ; Choi KS
Cancer Res; 2006 Feb; 66(3):1740-50. PubMed ID: 16452234
[TBL] [Abstract][Full Text] [Related]
8. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
Ishikawa E; Nakazawa M; Yoshinari M; Minami M
J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
[TBL] [Abstract][Full Text] [Related]
9. The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells.
Choi E; Kim Y; Kim K
Yonsei Med J; 2006 Feb; 47(1):55-62. PubMed ID: 16502485
[TBL] [Abstract][Full Text] [Related]
10. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis.
Smyth MJ; Cretney E; Takeda K; Wiltrout RH; Sedger LM; Kayagaki N; Yagita H; Okumura K
J Exp Med; 2001 Mar; 193(6):661-70. PubMed ID: 11257133
[TBL] [Abstract][Full Text] [Related]
12. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
[TBL] [Abstract][Full Text] [Related]
13. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation.
Jung EM; Park JW; Choi KS; Park JW; Lee HI; Lee KS; Kwon TK
Carcinogenesis; 2006 Oct; 27(10):2008-17. PubMed ID: 16613838
[TBL] [Abstract][Full Text] [Related]
14. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils.
Kamohara H; Matsuyama W; Shimozato O; Abe K; Galligan C; Hashimoto S; Matsushima K; Yoshimura T
Immunology; 2004 Feb; 111(2):186-94. PubMed ID: 15027904
[TBL] [Abstract][Full Text] [Related]
15. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
17. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).
Jung EM; Lim JH; Lee TJ; Park JW; Choi KS; Kwon TK
Carcinogenesis; 2005 Nov; 26(11):1905-13. PubMed ID: 15987718
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes.
Simon AK; Williams O; Mongkolsapaya J; Jin B; Xu XN; Walczak H; Screaton GR
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5158-63. PubMed ID: 11309507
[TBL] [Abstract][Full Text] [Related]
19. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.
Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS
Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670
[TBL] [Abstract][Full Text] [Related]
20. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
